Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in symptomatic DVT compared with placebo (low certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
DOAC probably leads to lower any VTE compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic VTE compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in major bleeding compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
It is very uncertain whether vitamin K antagonists changes symptomatic PE compared with placebo or no thromboprophylaxis (very low certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Vitamin K antagonists showed no clear difference in symptomatic DVT compared with placebo or no thromboprophylaxis (low certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
DOAC showed no clear difference in clinically relevant bleeding compared with placebo (moderate certainty).
1 finding from 1 review
All cause mortality (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Adverse events (timing not specified) · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bleeding (timing not specified) · people undergoing major amputation of the lower extremity
1 finding from 1 review
Total VTE · people undergoing major amputation of the lower extremity
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found